Bristol-Myers Squibb Company
BMYHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframeBristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. At a $132.14B market cap, Bristol-Myers Squibb Company ranks as a large-cap company within healthcare. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications.
Market Cap
$132.14B
Beta
0.23
P/E (TTM)
14.25
P/E (Fwd)
9.86
EPS (TTM)
$4.54
EPS (Fwd)
$6.56
ROE
46.6%
ROA
10.7%
Cash
$11.07B
Total Debt
$45.05B
Free CF
$8.11B
52W Change
41.7%
Annual Financials
Cash vs Debt
Where BMY stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, BMY finished 13.42% above its 150-day moving average ($59.00) and 17.44% above its 200-day moving average ($56.98). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BMY overbought or oversold?
At the September 2, 2026 close, BMY's RSI(14) was 63.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $11.07B in cash, though total debt stands at $45.05B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $8.11B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 46.6% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 10.7% further supports the picture of efficient asset utilization. Revenue has been relatively flat, moving from $46.16B (2022) to $48.20B (2025).
With a beta below 0.7, Bristol-Myers Squibb Company typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Bristol-Myers Squibb Company and its sector.